Therapeutics in Duchenne Muscular Dystrophy

NeuroRx

Volumn 3, Issue 2, 2006, Pages 225-234

  Strober, Jonathan B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

corticosteroids; Duchenne; gene therapy; muscular dystrophy; stem cell therapy

Indexed keywords

3 HYDROXY 3 METHYLGLUTARIC ACID; ADENOVIRUS VECTOR; ALENDRONIC ACID; AMINOGLYCOSIDE; ANTISENSE OLIGONUCLEOTIDE; ARGININE; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CONJUGATED LINOLEIC ACID; CORTICOSTEROID; CREATINE; CYCLOSPORIN; DEFLAZACORT; DYSTROPHIN; GENTAMICIN; LENTIVIRUS VECTOR; MYOSTATIN; OXANDROLONE; PLASMID VECTOR; PREDNISONE; THIOCTIC ACID; VITAMIN D; ANTIBODY; TRANSFORMING GROWTH FACTOR BETA;

ABSENCE OF SIDE EFFECTS; ACNE; ARTICLE; B LYMPHOCYTE; BEHAVIOR DISORDER; BONE DENSITY; BREATHING EXERCISE; CAPILLARY RESISTANCE; CATARACT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; CUSHINGOID SYNDROME; DNA REPAIR; DOSE RESPONSE; DRUG MECHANISM; DRUG TOLERABILITY; DUCHENNE MUSCULAR DYSTROPHY; EXERCISE; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GENE TRANSFER; GLUCOSURIA; HAIR GROWTH; HUMAN; INTERMITTENT POSITIVE PRESSURE VENTILATION; MONONUCLEAR CELL; MUSCLE BIOPSY; MUSCLE CONTRACTURE; NONHUMAN; NONSENSE MUTATION; NUTRITIONAL SUPPORT; POINT MUTATION; POSTOPERATIVE PERIOD; QUALITY OF LIFE; SCOLIOSIS; SIDE EFFECT; STATISTICAL SIGNIFICANCE; STEM CELL TRANSPLANTATION; SURGICAL TECHNIQUE; VIRAL GENE THERAPY; VITAL CAPACITY; VITAMIN SUPPLEMENTATION; WEIGHT GAIN; ANIMAL; DIET THERAPY; DRUG ANTAGONISM; GENE THERAPY; IMMUNOLOGY; MOUSE; REVIEW;

ADRENAL CORTEX HORMONES; AMINOGLYCOSIDES; ANIMALS; ANTIBODIES; GENE THERAPY; HUMANS; MICE; MUSCULAR DYSTROPHY, DUCHENNE; NUTRITION THERAPY; STEM CELL TRANSPLANTATION; TRANSFORMING GROWTH FACTOR BETA;

EID: 33646133422     PISSN: 15455343     EISSN: 15455351     Source Type: Journal    
DOI: 10.1016/j.nurx.2006.01.005     Document Type: Article

References (97)

1. Beenakker E.A., Maurits N.M., Fock J.M., Brouwer O.F., and van der Hoeven J.H. Functional ability and muscle force in healthy children and ambulant Duchenne muscular dystrophy patients. Eur J Paediatr Neurol (2005)
2. Kroksmark A.K., Beckung E., and Tulinius M. Muscle strength and motor function in children and adolescents with spinal muscular atrophy II and III. Eur J Paediatr Neurol 5 (2001) 191-198
3. Merlini L., Bertini E., Minetti C., Mongini T., Morandi L., Angelini C., et al. Motor function-muscle strength relationship in spinal muscular atrophy. Muscle Nerve 29 (2004) 548-552
4. Escolar D.M., Buyse G., Henricson E., Leshner R., Florence J., Mayhew J., et al. CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy. Ann Neurol 58 (2005) 151-155
5. Brooke M.H., Fenichel G.M., Griggs R.C., Mendell J.R., Moxley R., Florence J., et al. Duchenne muscular dystrophy. patterns of clinical progression and effects of supportive therapy. Neurology 39 (1989) 475-481
6. Ansved T. Muscular dystrophies. influence of physical conditioning on the disease evolution. Curr Opin Clin Nutr Metab Care 6 (2003) 435-439
7. Eagle M. Report on the muscular dystrophy campaign workshop. exercise in neuromuscular diseases Newcastle, January 2002. Neuromuscul Disord 12 (2002) 975-983
8. de Lateur B.J., and Giaconi R.M. Effect on maximal strength of submaximal exercise in Duchenne muscular dystrophy. Am J Phys Med 58 (1979) 26-36
9. Scott O.M., Hyde S.A., Vrbova G., and Dubowitz V. Therapeutic possibilities of chronic low frequency electrical stimulation in children with Duchenne muscular dystrophy. J Neurol Sci 95 (1990) 171-182
10. Dubowitz V. Responses of diseased muscle to electrical and mechanical intervention. Ciba Found Symp 138 (1988) 240-255
11. Do T. Orthopedic management of the muscular dystrophies. Curr Opin Pediatr 14 (2002) 50-53
12. Bach J.R. The historical role of the physiatrist in the management of Duchenne muscular dystrophy. A commentary. Am J Phys Med Rehabil 75 (1996) 239-241
13. Schramm C.M. Current concepts of respiratory complications of neuromuscular disease in children. Curr Opin Pediatr 12 (2000) 203-207
14. Bach J.R., Ishikawa Y., and Kim H. Prevention of pulmonary morbidity for patients with Duchenne muscular dystrophy. Chest 112 (1997) 1024-1028
15. Simonds A.K., Muntoni F., Heather S., and Fielding S. Impact of nasal ventilation on survival in hypercapnic Duchenne muscular dystrophy. Thorax 53 (1998) 949-952
16. Birnkrant D.J., Pope J.F., and Eiben R.M. Management of the respiratory complications of neuromuscular diseases in the pediatric intensive care unit. J Child Neurol 14 (1999) 139-143
17. Drachman D.B., Toyka K.V., and Myer E. Prednisone in Duchenne muscular dystrophy. Lancet 2 (1974) 1409-1412
18. Siegel I.M., Miller J.E., and Ray R.D. Failure of corticosteroid in the treatment of Duchenne (pseudo-hypertrophic) muscular dystrophy. Report of a clinically matched three year double-blind study. IMJ Ill Med J 145 (1974) 32-33
19. Brooke M.H., Fenichel G.M., Griggs R.C., Mendell J.R., Moxley III R.T., Miller J.P., et al. Clinical investigation of Duchenne muscular dystrophy. Interesting results in a trial of prednisone. Arch Neurol 44 (1987) 812-827
20. DeSilva S., Drachman D.B., Mellits D., and Kuncl R.W. Prednisone treatment in Duchenne muscular dystrophy. Long-term benefit. Arch Neurol 44 (1987) 818-822
21. Mendell J.R., Moxley R.T., Griggs R.C., Brooke M.H., Fenichel G.M., Miller J.P., et al. Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N Engl J Med 320 (1989) 1592-1597
22. Manzur A.Y., Kuntzer T., Pike M., and Swan A. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev 2 (2004) CD003725
23. Griggs R.C., Moxley III R.T., Mendell J.R., Fenichel G.M., Brooke M.H., Pestronk A., et al., Clinical Investigation of Duchenne Dystrophy Group. Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. Arch Neurol 48 (1991) 383-388
24. Fenichel G.M., Mendell J.R., Moxley III R.T., Griggs R.C., Brooke M.H., Miller J.P., et al. A comparison of daily and alternate-day prednisone therapy in the treatment of Duchenne muscular dystrophy. Arch Neurol 48 (1991) 575-579
25. Fenichel G.M., Florence J.M., Pestronk A., Mendell J.R., Moxley III R.T., Griggs R.C., et al. Long-term benefit from prednisone therapy in Duchenne muscular dystrophy. Neurology 41 (1991) 1874-1877
26. Griggs R.C., Moxley III R.T., Mendell J.R., Fenichel G.M., Brooke M.H., Pestronk A., et al. Duchenne dystrophy. randomized, controlled trial of prednisone (18 months) and azathioprine (12 months). Neurology 43 3 Pt 1 (1993) 520-527
27. Sansome A., Royston P., and Dubowitz V. Steroids in Duchenne muscular dystrophy; pilot study of a new low-dosage schedule. Neuromuscul Disord 3 (1993) 567-569
28. Kinali M., Mercuri E., Main M., Muntoni F., and Dubowitz V. An effective, low-dosage, intermittent schedule of prednisolone in the long-term treatment of early cases of Duchenne dystrophy. Neuromuscul Disord 12 Suppl 1 (2002) S169-S174
29. Connolly A.M., Schierbecker J., Renna R., and Florence J. High dose weekly oral prednisone improves strength in boys with Duchenne muscular dystrophy. Neuromuscul Disord 12 (2002) 917-925
30. Hawker G.A., Ridout R., Harris V.A., Chase C.C., Fielding L.J., and Biggar W.D. Alendronate in the treatment of low bone mass in steroid-treated boys with Duchennes muscular dystrophy. Arch Phys Med Rehabil 86 (2005) 284-288
31. Merlini L., Cicognani A., Malaspina E., Gennari M., Gnudi S., Talim B., et al. Early prednisone treatment in Duchenne muscular dystrophy. Muscle Nerve 27 (2003) 222-227
32. Markham L.W., Spicer R.L., Khoury P.R., Wong B.L., Mathews K.D., and Cripe L.H. Steroid Therapy and Cardiac Function in Duchenne Muscular Dystrophy. Pediatr Cardiol (2005)
33. Mesa L.E., Dubrovsky A.L., Corderi J., Marco P., and Flores D. Steroids in Duchenne muscular dystrophy-deflazacort trial. Neuromuscul Disord 1 (1991) 261-266
34. Angelini C., Pegoraro E., Perini F., Turella E., Intino M., Pini A., et al. A trial with a new steroid in Duchenne Muscular Dystrophy. In: Angelini C., Danieli G.A., and Fontanari D. (Eds). Muscular dystrophy research (1991), Elsevier, New York, NY 173-179
35. Angelini C., Pegoraro E., Turella E., Intino M.T., Pini A., and Costa C. Deflazacort in Duchenne dystrophy. study of long-term effect. Muscle Nerve 17 (1994) 386-391
36. Biggar W.D., Gingras M., Fehlings D.L., Harris V.A., and Steele C.A. Deflazacort treatment of Duchenne muscular dystrophy. J Pediatr 138 (2001) 45-50
37. Biggar W.D., Politano L., Harris V.A., Passamano L., Vajsar J., Alman B., et al. Deflazacort in Duchenne muscular dystrophy. a comparison of two different protocols. Neuromuscul Disord 14 8-9 (2004) 476-482
38. Campbell C., and Jacob P. Deflazacort for the treatment of Duchenne Dystrophy. a systematic review. BMC Neurol 3 (2003) 7
39. Silversides C.K., Webb G.D., Harris V.A., and Biggar D.W. Effects of deflazacort on left ventricular function in patients with Duchenne muscular dystrophy. Am J Cardiol 91 (2003) 769-772
40. Bonifati M.D., Ruzza G., Bonometto P., Berardinelli A., Gorni K., Orcesi S., et al. A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle Nerve 23 (2000) 1344-1347
41. Moxley III R.T., Ashwal S., Pandya S., Connolly A., Florence J., Mathews K., et al. Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 64 (2005) 13-20
42. Fenichel G.M., Griggs R.C., Kissel J., Kramer T.I., Mendell J.R., Moxley R.T., et al. A randomized efficacy and safety trial of oxandrolone in the treatment of Duchenne dystrophy. Neurology 56 (2001) 1075-1079
43. Kissel J.T., Burrow K.L., Rammohan K.W., Mendell J.R., and CIDD Study Group. Mononuclear cell analysis of muscle biopsies in prednisone-treated and untreated Duchenne muscular dystrophy. Neurology 41 (1991) 667-672
44. Kissel J.T., Lynn D.J., Rammohan K.W., Klein J.P., Griggs R.C., Moxley R.T., 3rd, et al. Mononuclear cell analysis of muscle biopsies in prednisone- and azathioprine-treated Duchenne muscular dystrophy. Neurology 43 3 Pt 1 (1993) 532-536
45. Fisher I., Abraham D., Bouri K., Hoffman E.P., Muntoni F., and Morgan J. Prednisolone-induced changes in dystrophic skeletal muscle. Faseb J 19 (2005) 834-836
46. Tinsley J.M., Blake D.J., Pearce M., Knight A.E., Kendrick-Jones J., and Davies K.E. Dystrophin and related proteins. Curr Opin Genet Dev 3 (1993) 484-490
47. Stupka N., Gregorevic P., Plant D.R., and Lynch G.S. The calcineurin signal transduction pathway is essential for successful muscle regeneration in mdx dystrophic mice. Acta Neuropathol (Berl) 107 (2004) 299-310
48. De Luca A., Nico B., Liantonio A., Didonna M.P., Fraysse B., Pierno S., et al. A multidisciplinary evaluation of the effectiveness of cyclosporine a in dystrophic mdx mice. Am J Pathol 166 (2005) 477-489
49. Sharma K.R., Mynhier M.A., and Miller R.G. Cyclosporine increases muscular force generation in Duchenne muscular dystrophy. Neurology 43 3 Pt 1 (1993) 527-532
50. Anderson J.E., McIntosh L.M., and Poettcker R. Deflazacort but not prednisone improves both muscle repair and fiber growth in diaphragm and limb muscle in vivo in the mdx dystrophic mouse. Muscle Nerve 19 (1996) 1576-1585
51. Tarnopolsky M., and Martin J. Creatine monohydrate increases strength in patients with neuromuscular disease. Neurology 52 (1999) 854-857
52. Passaquin A.C., Renard M., Kay L., Challet C., Mokhtarian A., Wallimann T., et al. Creatine supplementation reduces skeletal muscle degeneration and enhances mitochondrial function in mdx mice. Neuromuscul Disord 12 (2002) 174-182
53. Tarnopolsky M.A., Mahoney D.J., Vajsar J., Rodriguez C., Doherty T.J., Roy B.D., et al. Creatine monohydrate enhances strength and body composition in Duchenne muscular dystrophy. Neurology 62 (2004) 1771-1777
54. Voisin V., Sebrie C., Matecki S., Yu H., Gillet B., Ramonatxo M., et al. L-arginine improves dystrophic phenotype in mdx mice. Neurobiol Dis 20 (2005) 123-130
55. Chaubourt E., Voisin V., Fossier P., Baux G., Israel M., and De La Porte S. Muscular nitric oxide synthase (muNOS) and utrophin. J Physiol Paris 96 1-2 (2002) 43-52
56. Barton E.R., Morris L., Kawana M., Bish L.T., and Toursel T. Systemic administration of L-arginine benefits mdx skeletal muscle function. Muscle Nerve (2005)
57. Payne E.T., Yasuda N., Bourgeois J.M., Devries M.C., Rodriguez M.C., Yousuf J., et al. Nutritional therapy improves function and complements corticosteroid intervention in mdx mice. Muscle Nerve (2005)
58. Patel K., and Amthor H. The function of Myostatin and strategies of Myostatin blockade-new hope for therapies aimed at promoting growth of skeletal muscle. Neuromuscul Disord 15 (2005) 117-126
59. McPherron A.C., Lawler A.M., and Lee S.J. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 387 (1997) 83-90
60. Schuelke M., Wagner K.R., Stolz L.E., Hubner C., Riebel T., Komen W., et al. Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med 350 (2004) 2682-2688
61. Bogdanovich S., Krag T.O., Barton E.R., Morris L.D., Whittemore L.A., Ahima R.S., et al. Functional improvement of dystrophic muscle by myostatin blockade. Nature 420 (2002) 418-421
62. Wagner K.R., McPherron A.C., Winik N., and Lee S.J. Loss of myostatin attenuates severity of muscular dystrophy in mdx mice. Ann Neurol 52 (2002) 832-836
63. Benabdallah B.F., Bouchentouf M., and Tremblay J.P. Improved success of myoblast transplantation in mdx mice by blocking the myostatin signal. Transplantation 79 (2005) 1696-1702
64. Partridge T.A., Grounds M., and Sloper J.C. Evidence of fusion between host and donor myoblasts in skeletal-muscle grafts. Nature 273 (1978) 306-308
65. Watt D.J., Lambert K., Morgan J.E., Partridge T.A., and Sloper J.C. Incorporation of donor muscle precursor cells into an area of muscle regeneration in the host mouse. J Neurol Sci 57 2-3 (1982) 319-331
66. Watt D.J., Morgan J.E., and Partridge T.A. Use of mononuclear precursor cells to insert allogeneic genes into growing mouse muscles. Muscle Nerve 7 (1984) 741-750
67. Partridge T.A., Morgan J.E., Coulton G.R., Hoffman E.P., and Kunkel L.M. Conversion of mdx myofibres from dystrophin-negative to -positive by injection of normal myoblasts. Nature 337 (1989) 176-179
68. Mendell J.R., Kissel J.T., Amato A.A., King W., Signore L., Prior T.W., et al. Myoblast transfer in the treatment of Duchenne's muscular dystrophy. N Engl J Med 333 (1995) 832-838
69. Miller R.G., Sharma K.R., Pavlath G.K., Gussoni E., Mynhier M., Lanctot A.M., et al. Myoblast implantation in Duchenne muscular dystrophy. the San Francisco study. Muscle Nerve 20 (1997) 469-478
70. Law P.K. Myoblast transfer therapy. Lancet 341 (1993) 8839
71. Law P.K., Goodwin T.G., Fang Q., Hall T.L., Quinley T., Vastagh G., et al. First human myoblast transfer therapy continues to show dystrophin after 6 years. Cell Transplant 6 (1997) 95-100
72. Partridge T. Myoblast transplantation. Neuromuscul Disord 12 Suppl 1 (2002) S3-S6
73. Gussoni E., Bennett R.R., Muskiewicz K.R., Meyerrose T., Nolta J.A., Gilgoff I., et al. Long-term persistence of donor nuclei in a Duchenne muscular dystrophy patient receiving bone marrow transplantation. J Clin Invest 110 (2002) 807-814
74. Bittner R.E., Schofer C., Weipoltshammer K., Ivanova S., Streubel B., Hauser E., et al. Recruitment of bone-marrow-derived cells by skeletal and cardiac muscle in adult dystrophic mdx mice. Anat Embryol (Berl) 199 (1999) 391-396
75. Gussoni E., Soneoka Y., Strickland C.D., Buzney E.A., Khan M.K., Flint A.F., et al. Dystrophin expression in the mdx mouse restored by stem cell transplantation. Nature 401 (1999) 390-394
76. Wilton S.D., Dye D.E., Blechynden L.M., and Laing N.G. Revertant fibres. a possible genetic therapy for Duchenne muscular dystrophy?. Neuromuscul Disord 7 (1997) 329-335
77. Ferrari G., and Mavilio F. Myogenic stem cells from the bone marrow. a therapeutic alternative for muscular dystrophy?. Neuromuscul Disord 12 Suppl 1 (2002) S7-S10
78. Kochanek S., Clemens P.R., Mitani K., Chen H.H., Chan S., and Caskey C.T. A new adenoviral vector. Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase. Proc Natl Acad Sci U S A 93 (1996) 5731-5736
79. van Deutekom J.C., and van Ommen G.J. Advances in Duchenne muscular dystrophy gene therapy. Nat Rev Genet 4 (2003) 774-783
80. Dubowitz V. Special Centennial Workshop- 101st ENMC International Workshop. Therapeutic Possibilities in Duchenne Muscular Dystrophy, 30th November-2nd December 2001, Naarden, The Netherlands. Neuromuscul Disord 12 (2002) 421-431
81. Akkaraju G.R., Huard J., Hoffman E.P., Goins W.F., Pruchnic R., Watkins S.C., et al. Herpes simplex virus vector-mediated dystrophin gene transfer and expression in MDX mouse skeletal muscle. J Gene Med 1 (1999) 280-289
82. Huard J., Krisky D., Oligino T., Marconi P., Day C.S., Watkins S.C., et al. Gene transfer to muscle using herpes simplex virus-based vectors. Neuromuscul Disord 7 (1997) 299-313
83. Harper S.Q., Hauser M.A., DelloRusso C., Duan D., Crawford R.W., Phelps S.F., et al. Modular flexibility of dystrophin. implications for gene therapy of Duchenne muscular dystrophy. Nat Med 8 (2002) 253-261
84. Wang B., Li J., and Xiao X. Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. Proc Natl Acad Sci U S A 97 (2000) 13714-13719
85. Athanasopoulos T., Graham I.R., Foster H., and Dickson G. Recombinant adeno-associated viral (rAAV) vectors as therapeutic tools for Duchenne muscular dystrophy (DMD). Gene Ther 11 Suppl 1 (2004) S109-S121
86. Goncalves M.A., van Nierop G.P., Tijssen M.R., Lefesvre P., Knaan-Shanzer S., van der Velde I., et al. Transfer of the full-length dystrophin-coding sequence into muscle cells by a dual high-capacity hybrid viral vector with site-specific integration ability. J Virol 79 (2005) 3146-3162
87. Kapsa R., Kornberg A.J., and Byrne E. Novel therapies for Duchenne muscular dystrophy. Lancet Neurol 2 (2003) 299-310
88. Braun S., Thioudellet C., Rodriguez P., Ali-Hadji D., Perraud F., Accart N., et al. Immune rejection of human dystrophin following intramuscular injections of naked DNA in mdx mice. Gene Ther 7 (2000) 1447-1457
89. Romero N.B., Braun S., Benveniste O., Leturcq F., Hogrel J.Y., Morris G.E., et al. Phase I study of dystrophin plasmid-based gene therapy in Duchenne/Becker muscular dystrophy. Hum Gene Ther 15 (2004) 1065-1076
90. Rando T.A., Disatnik M.H., and Zhou L.Z. Rescue of dystrophin expression in mdx mouse muscle by RNA/DNA oligonucleotides. Proc Natl Acad Sci U S A 97 (2000) 5363-5368
91. van Deutekom J.C. Gene therapy. the 'pro-sense' approach to Duchenne muscular dystrophy. Eur J Hum Genet 13 (2005) 518-519
92. Lu Q.L., Mann C.J., Lou F., Bou-Gharios G., Morris G.E., Xue S.A., et al. Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse. Nat Med 9 (2003) 1009-1014
93. Muntoni F., Bushby K., and van Ommen G. 128th ENMC International Workshop on 'Preclinical optimization and Phase I/II Clinical Trials Using Antisense Oligonucleotides in Duchenne Muscular Dystrophy' 22-24 October 2004, Naarden, The Netherlands. Neuromuscul Disord 15 (2005) 450-457
94. Wells D.J., Ferrer A., and Wells K.E. Immunological hurdles in the path to gene therapy for Duchenne muscular dystrophy. Expert Rev Mol Med 2002 (2002) 1-23
95. Wilton S.D., and Fletcher S. Antisense oligonucleotides in the treatment of Duchenne muscular dystrophy. Where are we now?. Neuromuscul Disord 15 (2005) 399-402
96. Barton-Davis E.R., Cordier L., Shoturma D.I., Leland S.E., and Sweeney H.L. Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J Clin Invest 104 (1999) 375-381
97. Wagner K.R., Hamed S., Hadley D.W., Gropman A.L., Burstein A.H., Escolar D.M., et al. Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations. Ann Neurol 49 (2001) 706-711